The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial.
James Paul Dean
No relevant relationships to disclose
Robert B. Montgomery
No relevant relationships to disclose
Junxiang Wan
No relevant relationships to disclose
Pinchas Cohen
No relevant relationships to disclose
Kathleen Haugk
No relevant relationships to disclose
John M Corman
No relevant relationships to disclose
William J Ellis
No relevant relationships to disclose
Bruce L Dalkin
No relevant relationships to disclose
Dale L. Ludwig
No relevant relationships to disclose
Stephen R Plymate
No relevant relationships to disclose